“…Numerous studies assessing the adverse events (AEs) and effectiveness of HITH and OPAT have been performed in many countries including Australia, 2,9,[19][20][21][22][23][24][25][26] USA, [27][28][29][30][31][32][33][34][35][36][37][38][39][40] UK, 4,[41][42][43][44][45] Spain, 3,8,11,15,46 France, 47,48 Singapore, 12,49 Israel, 50 Canada, 51 Italy, 17 Ireland, 52 New Zealand, 53 Saudi Arabia, 54 Switzerland 55 and Greece. 56 Some studies have analysed the safety of HITH or OPAT for a particular disease or for a particular group including geriatric 11,15,17,…”